Our study also has immediate clinical implications, as it confirms the need to stratify patients with HR+ BC on the basis of their ER levels, in addition to LCOR levels, as biomarkers for optimized clinical benefit of immune-based therapies. This evidence concerns the gene ESR1 and breast cancer.